The LDL Target Keeps Falling: From <100 to <70 to <55 — Are We There Yet?

Twenty years ago, if you told a stroke neurologist that we'd one day be targeting LDL levels below 55 mg/dL in our patients, they would have looked at you skeptically. The brain needs cholesterol, doesn't it? Won't we cause hemorrhagic strokes? What about cognitive decline?

Today, the 2026 ACC/AHA guidelines recommend exactly that target for very high-risk atherosclerotic cardiovascular disease (ASCVD) patients — and most of our stroke patients qualify. The journey from <100 to <70 to <55 mg/dL wasn't arbitrary. It was built on three landmark trials that fundamentally changed how we think about lipid management after stroke.

Let's walk through this evolution step by step, because understanding how the evidence developed helps us understand why we're treating more aggressively — and addresses the safety concerns that still make some clinicians hesitant to push LDL this low.

The Early Era: When Statins Weren't Standard After Stroke

Before 2006, secondary stroke prevention meant aspirin, blood pressure control, and vague advice about "lifestyle modification." High-intensity statins were gaining traction in cardiology, but stroke was different, we told ourselves. The brain has unique vulnerabilities. Cerebral small vessels are delicate. And besides, most strokes weren't even atherosclerotic.

The prevailing LDL target — borrowed from cardiology guidelines — was <100 mg/dL. But this was more aspirational than evidence-based for stroke patients specifically. We simply didn't know whether aggressive lipid lowering would help, harm, or do nothing after cerebrovascular events.

Then came SPARCL.

Published in the New England Journal of Medicine in 2006, the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial randomized 4,731 patients with recent stroke or TIA to atorvastatin 80 mg daily versus placebo. These weren't selected for high cholesterol — the mean baseline LDL was 133 mg/dL, which many clinicians at the time considered acceptable for stroke patients.

The treatment group's LDL fell to 73 mg/dL. Over five years of follow-up, atorvastatin reduced recurrent stroke by 16% (HR 0.84) and major cardiovascular events by 20%. The number needed to treat to prevent one stroke was 46 over five years — not spectacular, but clinically meaningful for a daily pill.

SPARCL established high-intensity statin therapy as standard of care after ischemic stroke. It gave us our first real target to aim for in stroke patients: get LDL down to the 70s, because that's where the benefit appeared.

But there was a problem that would haunt lipid discussions for the next fifteen years.

The Hemorrhagic Stroke Signal

Atorvastatin didn't just reduce ischemic events — it appeared to increase hemorrhagic stroke. There were 55 hemorrhagic strokes in the treatment group versus 33 in placebo (HR 1.66). This wasn't a subtle trend; it was a statistically significant increase in the outcome we most fear as stroke neurologists.

The increase was concentrated in patients with prior hemorrhagic stroke (a group that probably shouldn't have been enrolled) and those with lacunar infarcts (suggesting underlying small vessel disease). But the signal was real, and it raised an uncomfortable question: Are we trading ischemic strokes for hemorrhagic ones?

This concern shaped clinical practice for years. Neurologists became cautious about intensive statins in patients with microbleeds, prior hemorrhage, or extensive white matter disease. Guidelines hedged their recommendations. And the idea that "too low" LDL might be dangerous took root, even without strong mechanistic evidence.

The question remained: Was LDL in the 70s low enough to maximize benefit but not so low as to cause harm? Or could we — should we — go lower?

The Shift to LDL <70: Testing Targets Head-to-Head

SPARCL told us that lowering LDL reduces stroke risk. But it was a comparison against placebo, leaving a crucial question unanswered: What specific LDL level should we target?

Cardiology was already moving toward <70 mg/dL for high-risk patients, but this was extrapolated from trials in coronary disease. Stroke patients weren't included in sufficient numbers to draw independent conclusions. We were prescribing based on assumption, not evidence.

The 2021 AHA/ASA Secondary Prevention Guidelines codified <70 mg/dL as the target for atherosclerotic stroke (Class I recommendation, Level of Evidence A). They recommended statin plus ezetimibe to achieve this goal, and noted that PCSK9 inhibitors were reasonable for very high-risk patients who couldn't reach target (Class IIa recommendation).

But here's what's interesting: Those guidelines were published in 2021, citing a trial from 2020 that directly tested whether the <70 target made sense.

Treat Stroke to Target: The First Trial to Compare LDL Goals

The Treat Stroke to Target (TST) trial, published in the New England Journal of Medicine in 2020, was the study we'd been waiting for. Instead of statin versus placebo, it compared two LDL targets: <70 mg/dL versus 90-110 mg/dL.

This matters more than it might seem. Up to this point, we knew statins worked, but we were guessing at the optimal target. TST directly tested the hypothesis that lower LDL provides additional benefit in stroke patients.

The trial enrolled 2,860 patients with ischemic stroke or TIA attributed to atherosclerosis — these were exactly the patients we see in clinic with carotid disease, intracranial stenosis, or aortic arch plaques. They were randomized to intensive versus standard LDL goals and followed for major cardiovascular events.

The results were clear: The lower-target group (achieving LDL <70) had fewer major cardiovascular events than the standard-target group (8.5% vs. 10.9%, HR 0.78, p=0.04). This was a composite endpoint including ischemic stroke, MI, urgent coronary or carotid revascularization, and cardiovascular death — all outcomes we care about preventing.

But what about the hemorrhagic stroke concern from SPARCL?

TST showed no significant increase in intracranial hemorrhage between groups (1.3% in the low-target group vs. 0.9% in the standard-target group). The rates were low in both arms, and the difference wasn't statistically or clinically significant. There was also no meaningful increase in new-onset diabetes (7.2% vs. 5.7%).

This was the evidence that allowed guidelines to confidently recommend <70 mg/dL as a target. TST proved that achieving this level in stroke patients reduces recurrent events without the safety concerns that had made clinicians hesitant.

The question then became: If <70 is better than 90-110, and we're already using high-intensity statins plus ezetimibe to get there, have we reached the floor? Or is there room to go lower still?

The New Frontier: LDL <55 mg/dL in Very High-Risk Patients

The 2026 ACC/AHA Dyslipidemia Guidelines represent the next evolution. For very high-risk ASCVD patients — a category that includes most stroke patients with atherosclerotic disease — the recommended LDL target is now <55 mg/dL.

This wasn't pulled from thin air. It's based on the Ez-PAVE trial, published in the New England Journal of Medicine in 2026, which tested whether pushing LDL below 55 mg/dL provides additional cardiovascular benefit compared to the now-standard target of <70 mg/dL.

Ez-PAVE: Testing the Limits of "Lower Is Better"

Ez-PAVE enrolled 3,048 patients with established atherosclerotic cardiovascular disease — including those with prior stroke, MI, or peripheral artery disease — and randomized them to LDL targets of <55 mg/dL versus <70 mg/dL. The intensive group achieved a median LDL of 56 mg/dL, while the standard group reached 66 mg/dL.

The primary endpoint was a composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization, and unstable angina hospitalization. Over the follow-up period, the intensive group had significantly fewer events: 6.6% versus 9.7% (HR 0.67, p=0.002).

This is a 33% relative risk reduction — and the number needed to treat is approximately 32 patients to prevent one major cardiovascular event. For a strategy as simple as adding ezetimibe to a statin, that's clinically meaningful.

What makes Ez-PAVE particularly relevant for stroke clinicians is how they achieved these ultra-low LDL levels. This wasn't primarily a PCSK9 inhibitor trial — only 2.3% of patients used them. Instead, 66.6% of patients in the intensive group were on ezetimibe, often added to high-intensity statin therapy. This is a generic, inexpensive, once-daily pill that we can prescribe without prior authorization battles.

The trial was pragmatic in this way. It showed that the <55 target is achievable in routine practice with medications already widely available.

Safety at the Extremes

Every time we push LDL lower, the same concerns resurface: What about bleeding? Cognitive decline? Muscle toxicity? Cancer risk? And the perennial question for neurologists — are we going to cause hemorrhagic strokes?

Ez-PAVE addressed these systematically. There was no increase in new-onset diabetes (16.6% in the intensive group vs. 16.1% in the standard group). Muscle symptoms weren't different between groups. Cancer rates were similar. Liver enzyme elevations trended slightly higher in the intensive group (2.4% vs. 1.5%) but didn't reach statistical significance.

Most importantly for stroke neurologists: There was no signal for increased hemorrhagic stroke or intracranial hemorrhage at LDL levels in the mid-50s.

The trial had limitations. It was open-label, conducted primarily in an East Asian population, and only 60.8% of patients in the intensive group actually achieved LDL <55 at three years — suggesting that real-world adherence and dose titration remain challenges. But the safety profile was reassuring across the range of LDL levels achieved.

Addressing the Persistent Concerns: Is Too Low Dangerous?

Despite mounting evidence, many clinicians remain uneasy about pushing LDL to 55 mg/dL or lower, especially in stroke patients. The concerns are understandable — they're rooted in biological plausibility and the SPARCL hemorrhagic stroke signal that we discussed earlier. Let's address them directly.

The Hemorrhagic Stroke Question

The SPARCL finding — that high-dose atorvastatin increased hemorrhagic stroke risk — has been difficult to shake from our collective consciousness. But subsequent data hasn't confirmed this as a consistent effect of low LDL levels.

TST, which compared LDL targets of <70 versus 90-110 mg/dL, showed no increased intracranial hemorrhage risk in the lower-LDL group. The rates were 1.3% versus 0.9% — numerically higher, but not statistically or clinically significant given the small absolute numbers.

Ez-PAVE, pushing LDL below 55 mg/dL, similarly showed no safety signal for bleeding complications or hemorrhagic stroke.

So what explains SPARCL? The most likely explanation is patient selection and chance. The hemorrhagic strokes in SPARCL clustered in patients with prior hemorrhage (who probably shouldn't have been enrolled) and those with lacunar strokes suggesting severe small vessel disease. There's also the possibility that atorvastatin specifically — rather than low LDL per se — had effects on vessel wall integrity at very high doses in susceptible patients.

The broader evidence suggests that low LDL levels achieved through various mechanisms (statins, ezetimibe, PCSK9 inhibitors) don't consistently increase hemorrhagic stroke risk. This doesn't mean we should ignore imaging findings like extensive microbleeds or advanced small vessel disease, but it does mean that LDL <55 mg/dL isn't inherently dangerous from a bleeding standpoint.

Cognitive Concerns

The brain is 60% fat. Cholesterol is essential for synapse formation, myelin maintenance, and neurotransmitter function. Doesn't it follow that very low serum cholesterol might impair cognition?

The short answer is no — because the brain synthesizes its own cholesterol. Serum LDL doesn't cross the blood-brain barrier in meaningful amounts. The cholesterol in your brain is made locally by glial cells, independent of what's circulating in your bloodstream.

Clinical data supports this. Multiple studies, including cognitive substudies from the FOURIER trial of PCSK9 inhibitors, have shown no cognitive decline with very low LDL levels — including patients achieving LDL <25 mg/dL. If there were a threshold below which cognition suffered, we would have found it by now.

This doesn't mean we shouldn't monitor cognition in elderly patients on multiple medications. But LDL levels in the 50s aren't the culprit when we do see cognitive changes.

Metabolic and Systemic Safety

Statins increase diabetes risk — this has been confirmed across multiple trials. The question is whether pushing to lower LDL targets with additional agents amplifies this risk.

Current data suggests not. TST showed similar diabetes rates between the <70 and 90-110 groups (7.2% vs. 5.7%). Ez-PAVE showed nearly identical rates at <55 versus <70 (16.6% vs. 16.1%). The diabetes risk appears to be a statin effect, not a low-LDL effect.

Muscle symptoms remain the most common reason patients discontinue statins. But adding ezetimibe to achieve lower targets doesn't increase myalgia — ezetimibe works in the gut, not in muscle tissue. PCSK9 inhibitors, when needed, also don't cause muscle symptoms.

The practical implication: If a patient tolerates a statin, they'll likely tolerate the addition of ezetimibe to reach a lower target. The side effect profile doesn't worsen as LDL falls.

Where Experts Still Disagree

Despite increasingly strong evidence for lower LDL targets, clinical practice remains variable. Walk into five different stroke clinics and you'll find five different approaches to lipid management after stroke. Some of this reflects legitimate clinical equipoise; some reflects inertia.

Who Qualifies as "Very High Risk"?

The 2026 guidelines recommend LDL <55 mg/dL for very high-risk ASCVD patients. But what defines "very high risk" in the stroke population?

Most guidelines include patients with: multiple major ASCVD events (e.g., prior stroke plus prior MI), recurrent events despite maximally tolerated statin therapy, or a single major ASCVD event with multiple high-risk conditions (diabetes, CKD, current smoking, persistently elevated LDL despite treatment).

By these criteria, many — perhaps most — of our stroke patients with large-artery atherosclerosis qualify as very high risk. The 65-year-old with carotid stenosis, diabetes, and hypertension? Very high risk. The patient with recurrent TIAs despite statin therapy? Very high risk.

Some experts argue that all atherosclerotic stroke patients should be treated to <55 mg/dL, reasoning that having a stroke is itself a very-high-risk event. Others reserve the <55 target for the subset with recurrent events or multiple vascular territories involved.

The evidence doesn't yet definitively answer this question. Ez-PAVE included broad ASCVD patients; it wasn't stroke-specific. A trial comparing <55 versus <70 specifically in stroke patients would settle the debate, but until then, clinical judgment applies.

The Role of PCSK9 Inhibitors

PCSK9 inhibitors (evolocumab, alirocumab) are extraordinarily effective at lowering LDL — they can reduce levels by 50-60% when added to statin therapy. They've been shown to reduce cardiovascular events in high-risk populations.

But they're expensive, require injections every 2-4 weeks, and face significant insurance barriers. The 2021 stroke guidelines give them a Class IIa recommendation (reasonable to use) for very high-risk patients not at goal with statin plus ezetimibe.

Here's where practice patterns diverge. Some academic centers use PCSK9 inhibitors liberally in stroke patients with persistent LDL elevation. Community neurologists rarely prescribe them, citing cost, access, and the burden of prior authorization.

Ez-PAVE showed that most patients can reach LDL <55 with statin plus ezetimibe — only 2.3% needed PCSK9 inhibitors. This suggests we should exhaust cheaper, simpler options first. But for the patient who's had two strokes despite statin and ezetimibe, with LDL still at 85 mg/dL? That's when the conversation about PCSK9 inhibitors becomes worth having.

The real barrier isn't evidence — it's access. Insurance denials remain common, and many patients can't afford the out-of-pocket cost even with manufacturer assistance programs.

The "Good Enough" Debate

There's a pragmatic question lurking beneath all of this: Even if <55 is marginally better than <70, is the juice worth the squeeze?

Ez-PAVE showed a number needed to treat of 32 to prevent one major cardiovascular event. That's clinically meaningful, but it also means 31 out of 32 patients won't see a difference between the two targets. For a patient already on a statin who's reached LDL of 68 mg/dL, do we add ezetimibe to get them to 52 mg/dL?

Some experts say yes — it's one more pill, inexpensive, well-tolerated, and backed by randomized evidence. Others say focus on the bigger picture: medication adherence, blood pressure control, smoking cessation, diabetes management. Don't chase a number at the expense of the therapeutic relationship.

This is where the evidence meets individual patient care. For a motivated 55-year-old who's devastated by their stroke and wants to do everything possible to prevent another one? Absolutely add ezetimibe to reach <55. For an 85-year-old on ten medications with marginal adherence? Maybe LDL of 75 on a statin alone is sufficient.

Guidelines give us targets. Clinical judgment decides which patients need to hit them.

Practical Takeaway: A Stepwise Approach to Modern Lipid Management

Let's bring this back to Monday morning clinic. Your patient had an ischemic stroke three months ago attributed to carotid atherosclerosis. They're on aspirin, their blood pressure is controlled, and you're reviewing their lipid panel. LDL is 95 mg/dL. What do you do?

Step 1: Start with High-Intensity Statin Therapy

If they're not already on one, initiate atorvastatin 40-80 mg or rosuvastatin 20-40 mg. This is the foundation — everything else builds from here. Aim for at least 50% LDL reduction from baseline.

Recheck lipids in 4-12 weeks. If LDL is <70 mg/dL and the patient isn't very high risk, you're done. If they're very high risk (and most atherosclerotic stroke patients are), your target is <55 mg/dL. Keep going.

Step 2: Add Ezetimibe 10 mg Daily

Ezetimibe inhibits cholesterol absorption in the gut. It lowers LDL by an additional 15-20% when added to a statin. It's once-daily, generic, inexpensive (often <$10/month), and extremely well-tolerated.

This is the step that gets most patients to goal. In Ez-PAVE, two-thirds of patients in the intensive arm were on ezetimibe, and the majority reached LDL <55 mg/dL with statin plus ezetimibe alone.

Recheck lipids in 4-12 weeks. If LDL is <55 mg/dL, you're done. If not, proceed to step 3.

Step 3: Consider a PCSK9 Inhibitor if Still Not at Goal

For the patient who's maximized statin dose, added ezetimibe, and still has LDL >55 mg/dL — especially if they've had recurrent events — this is when PCSK9 inhibitors enter the discussion.

Expect insurance hurdles. Document that the patient has had a stroke, is on maximally tolerated statin therapy, has added ezetimibe, and remains above goal despite this. Emphasize that they're very high risk (prior stroke, diabetes, etc.). Most insurers require a documented trial of statin plus ezetimibe before approving a PCSK9 inhibitor.

Evolocumab 140 mg every two weeks or alirocumab 75-150 mg every two weeks are the options. Both are subcutaneous injections. Manufacturer copay assistance programs can reduce out-of-pocket costs, but availability varies.

Monitoring and Follow-Up

Recheck lipids 4-12 weeks after any medication change. Once at goal, annual lipid panels are sufficient unless there's a change in clinical status or medication regimen.

Check baseline ALT before starting therapy and monitor if symptoms suggest hepatotoxicity (rare). Routine transaminase monitoring isn't necessary in asymptomatic patients.

The 2026 guidelines specifically recommend against CoQ10 supplementation for statin-associated muscle symptoms (Class III: No Benefit). If a patient has myalgias, try a different statin, lower the dose, or switch to alternate-day dosing before abandoning statins entirely.

So, Are We There Yet?

From <100 to <70 to <55 mg/dL in twenty years — each step downward was controversial, then evidence-based, then standard of care. It's a remarkable evolution, driven by trials that challenged our assumptions about how low is too low.

Will the target keep falling? Maybe. There are patients on PCSK9 inhibitors with LDL levels in the 20s and 30s without apparent harm. The "lower is better" hypothesis hasn't found a floor yet in terms of cardiovascular benefit or safety signals.

But for now, we have a clear, evidence-based target for very high-risk stroke patients: LDL <55 mg/dL. We have a stepwise approach to achieve it. And we have data showing that it's safe, effective, and achievable with medications that most patients can access and tolerate.

The real question isn't whether we're "there yet" — it's whether we're actually implementing what we already know. Guidelines are only as good as the clinicians who follow them. Walk out of a stroke clinic visit without addressing LDL, and you've missed one of the few interventions with Level A evidence for secondary prevention.

Twenty years ago, we didn't even prescribe statins routinely after stroke. Today, we're fine-tuning LDL targets down to the single digits of benefit. That's progress. And for the 32nd patient who avoids a recurrent stroke because we pushed their LDL from 68 to 52 mg/dL, it's progress that matters.